Evidence map›Paper›PMID 42239834›Full record

ArticleCurrent opinion in endocrine and metabolic research2023

Erythropoietin and Skeletal Cells CrossTalks in Physiology and Disease.

Giulia Lanzolla, Mohd Parvez Khan, Elena Sabini, Amato Giaccia, Ernestina Schipani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current opinion in endocrine and metabolic research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Giulia LanzollaDepartment of Orthopaedic Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, 19104, PA, USA.
Mohd Parvez KhanDepartment of Orthopaedic Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, 19104, PA, USA.
Elena SabiniDepartment of Orthopaedic Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, 19104, PA, USA.
Amato GiacciaMRC Oxford Institute for Radiation Oncology, University of Oxford, University of Oxford, Oxford OX3 7DQ, UK.
Ernestina SchipaniDepartment of Orthopaedic Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, 19104, PA, USA.

Funding

Mitochondria and TFAM in Osteoblast BiologyR01AR074079 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI SCHIPANI, ERNESTINA · 2019 to 2024
$2.0M
HIF-2alpha, a Novel Regulator of OsteoblastogenesisR01AR073022 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI SCHIPANI, ERNESTINA · 2019 to 2023
$1.7M
NIAMS NIH HHS R01 AR073022NIAMS NIH HHS R01 AR074079
6 · The paper itself

Abstract

The hypoxia-inducible factor 2alpha (HIF-2), which is a member of the HIF family of transcription factors and a critical component of the hypoxia-driven pathway, regulates adult erythropoiesis through the renal production and secretion of erythropoietin (EPO). Notably, circulating EPO also affects bone mass through either direct or indirect actions on osteoblastic and osteoclastic cells. Adding complexity to the picture, we have recently reported that osteoblastic cells produce and secrete EPO upon activation of HIF-2. Although physiological role of osteoblastic EPO in controlling hematopoiesis remains to be determined, our findings could have translational implications for the treatment of anemia.

Indexed as

bone marrowErythropoietinhematopoiesisHypoxia-inducible-factor 2osteoblasts

Identifiers

PMID42239834
PMCPMC13229548

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.